J W Sweetenham

Summary

Affiliation: Cleveland Clinic Foundation
Country: USA

Publications

  1. ncbi request reprint Treatment of lymphoblastic lymphoma in adults
    John W Sweetenham
    Cleveland Clinic, Taussig Cancer Institute, Cleveland, Ohio 44195, USA
    Oncology (Williston Park) 23:1015-20. 2009
  2. doi request reprint Molecular signatures in the diagnosis and management of diffuse large B-cell lymphoma
    John W Sweetenham
    Cleveland Clinic, Taussig Cancer Institute, Cleveland, Ohio 44195, USA
    Curr Opin Hematol 18:288-92. 2011
  3. doi request reprint Lymphoblastic lymphoma in adults
    John W Sweetenham
    Hematology and Oncology R35, Cleveland Clinic Foundation, OH 44195, USA
    Curr Hematol Malig Rep 1:241-7. 2006
  4. doi request reprint Highly aggressive lymphomas in adults
    John W Sweetenham
    Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Hematol Oncol Clin North Am 22:965-78, ix. 2008
  5. pmc Prognostic value of regulatory T cells, lymphoma-associated macrophages, and MUM-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: a Southwest Oncology Group Study
    J W Sweetenham
    Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA
    Ann Oncol 21:1196-202. 2010
  6. doi request reprint Comparison of outcomes after auto-SCT for patients with relapsed diffuse large B-cell lymphoma according to previous therapy with rituximab
    S D Smith
    Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic, Cleveland, OH 44195, USA
    Bone Marrow Transplant 46:262-6. 2011
  7. ncbi request reprint Effect of prior rituximab on high-dose therapy and autologous stem cell transplantation in follicular lymphoma
    T Y Kang
    Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Center, Cleveland, OH 44195, USA
    Bone Marrow Transplant 40:973-8. 2007
  8. ncbi request reprint Patients mobilizing large numbers of CD34+ cells ('super mobilizers') have improved survival in autologous stem cell transplantation for lymphoid malignancies
    B J Bolwell
    Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Center, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Bone Marrow Transplant 40:437-41. 2007
  9. doi request reprint Superior survival after replacing oral with intravenous busulfan in autologous stem cell transplantation for non-Hodgkin lymphoma with busulfan, cyclophosphamide and etoposide
    Robert M Dean
    Taussig Cancer Institute, Cleveland Clinic, OH 44195, USA
    Br J Haematol 148:226-34. 2010
  10. doi request reprint High rate of survival in transformed lymphoma after autologous stem cell transplant: pathologic analysis and comparison with de novo diffuse large B-cell lymphoma
    Stephen D Smith
    Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA
    Leuk Lymphoma 50:1625-31. 2009

Collaborators

Detail Information

Publications13

  1. ncbi request reprint Treatment of lymphoblastic lymphoma in adults
    John W Sweetenham
    Cleveland Clinic, Taussig Cancer Institute, Cleveland, Ohio 44195, USA
    Oncology (Williston Park) 23:1015-20. 2009
    ..Emerging molecular data have identified potential new therapeutic targets with supporting preclinical data...
  2. doi request reprint Molecular signatures in the diagnosis and management of diffuse large B-cell lymphoma
    John W Sweetenham
    Cleveland Clinic, Taussig Cancer Institute, Cleveland, Ohio 44195, USA
    Curr Opin Hematol 18:288-92. 2011
    ..This review summarizes recent data on the relevance of molecular subtypes of diffuse large B-cell lymphoma to clinical management and the potential to use subtyping to direct therapy...
  3. doi request reprint Lymphoblastic lymphoma in adults
    John W Sweetenham
    Hematology and Oncology R35, Cleveland Clinic Foundation, OH 44195, USA
    Curr Hematol Malig Rep 1:241-7. 2006
    ..Identification of new therapeutic targets by further molecular studies is required...
  4. doi request reprint Highly aggressive lymphomas in adults
    John W Sweetenham
    Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Hematol Oncol Clin North Am 22:965-78, ix. 2008
    ..As with other subtypes of NHL, emerging data from gene-expression profiling and related techniques are helping to define these entities more precisely and identify potential new rational therapeutic targets...
  5. pmc Prognostic value of regulatory T cells, lymphoma-associated macrophages, and MUM-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: a Southwest Oncology Group Study
    J W Sweetenham
    Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA
    Ann Oncol 21:1196-202. 2010
    ..The purpose was to examine the prognostic impact of features of tumor cells and immune microenvironment in patients with follicular lymphoma treated with and without anti-CD20 monoclonal antibody therapy...
  6. doi request reprint Comparison of outcomes after auto-SCT for patients with relapsed diffuse large B-cell lymphoma according to previous therapy with rituximab
    S D Smith
    Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic, Cleveland, OH 44195, USA
    Bone Marrow Transplant 46:262-6. 2011
    ..Again, no differences in outcomes were observed. This suggests that auto-SCT may be equally effective in pts relapsing after first-line therapy including R, and should remain the standard of care for relapsed DLBCL...
  7. ncbi request reprint Effect of prior rituximab on high-dose therapy and autologous stem cell transplantation in follicular lymphoma
    T Y Kang
    Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Center, Cleveland, OH 44195, USA
    Bone Marrow Transplant 40:973-8. 2007
    ..In conclusion, these results suggest that the use of rituximab-based regimens for the treatment of FL does not compromise the effectiveness of HDT and ASCT as a salvage strategy in patients with FL...
  8. ncbi request reprint Patients mobilizing large numbers of CD34+ cells ('super mobilizers') have improved survival in autologous stem cell transplantation for lymphoid malignancies
    B J Bolwell
    Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Center, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Bone Marrow Transplant 40:437-41. 2007
    ..We conclude that patients had an improved ASCT outcome if large numbers of CD34+ cells were mobilized and infused. The explanation for this observation is unknown...
  9. doi request reprint Superior survival after replacing oral with intravenous busulfan in autologous stem cell transplantation for non-Hodgkin lymphoma with busulfan, cyclophosphamide and etoposide
    Robert M Dean
    Taussig Cancer Institute, Cleveland Clinic, OH 44195, USA
    Br J Haematol 148:226-34. 2010
    ..001). IV busulfan appears to provide better efficacy and lower toxicity than oral busulfan in ASCT with BuCyVP for NHL. Whether PK-based busulfan dosing can achieve further improvements in this setting is worthy of study...
  10. doi request reprint High rate of survival in transformed lymphoma after autologous stem cell transplant: pathologic analysis and comparison with de novo diffuse large B-cell lymphoma
    Stephen D Smith
    Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA
    Leuk Lymphoma 50:1625-31. 2009
    ..Immunohistochemistry did not predict relapse-free or overall survival, and ASCT afforded a high rate of PFS in patients with TL...
  11. ncbi request reprint Iodine 131 tositumomab in the treatment of non-Hodgkin's lymphoma
    Stephen Smith
    Cleveland Clinic Foundation, Department of Hematology Oncology, Taussig Cancer Center, 9500 Euclid Avenue R35, Cleveland, OH 44195, USA
    Future Oncol 3:255-62. 2007
    ..Randomized, comparative trials are needed to define its optimal clinical use...
  12. ncbi request reprint Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen
    S D Smith
    Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Taussig Cancer Center, Cleveland, OH 44195, USA
    Bone Marrow Transplant 40:239-43. 2007
    ..Kaplan-Meier 5-year overall survival (OS) and relapse-free survival (RFS) are 34 and 18%, respectively. These results suggest a poor outcome for patients with PTCL after ASCT, and new therapies for T-cell lymphoma are needed...
  13. doi request reprint Survival and predictors of outcome in patients with acute leukemia admitted to the intensive care unit
    Snehal G Thakkar
    Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio 44195, USA
    Cancer 112:2233-40. 2008
    ..Predictors of outcome and rates of successful discharge have not been defined for patients with acute leukemia admitted to intensive care units (ICUs) in the US...